IMMUNOCORE HOLDINGS PLC

(IMCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immunocore : Goldman Sachs Starts Immunocore Holdings at Neutral With $40 Price Target

03/02/2021 | 08:05am EDT


ę MT Newswires 2021
All news about IMMUNOCORE HOLDINGS PLC
05/11Immunocore Holdings Q1 Net Loss Narrows as Revenue Rises
MT
05/11Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, ..
CI
05/11Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
GL
04/18IMMUNOCORE : Corporate Presentation - April 2022
PU
04/07Immunocore to present at the 21st Annual Needham Healthcare Conference
AQ
04/04IMMUNOCORE : European Commission Approves KIMMTRAK« (tebentafusp) for the treatment of unr..
PU
04/04Immunocore Wins European Regulatory Ok of Kimmtrak for Unresectable or Metastatic Uveal..
MT
04/04European Commission Approves KIMMTRAK« (tebentafusp) for the treatment of unresectable ..
GL
04/04European Commission Approves KIMMTRAK« (tebentafusp) for the treatment of unresectable ..
GL
04/04European Commission Approves Immunocore Holdings plc's KIMMTRAK (Tebentafusp) for the T..
CI
More news
Analyst Recommendations on IMMUNOCORE HOLDINGS PLC
More recommendations
Financials
Sales 2022 83,5 M 104 M 104 M
Net income 2022 -89,2 M -111 M -111 M
Net cash 2022 226 M 280 M 280 M
P/E ratio 2022 -11,9x
Yield 2022 -
Capitalization 1 032 M 1 280 M 1 280 M
EV / Sales 2022 9,65x
EV / Sales 2023 10,9x
Nbr of Employees 324
Free-Float 36,5%
Chart IMMUNOCORE HOLDINGS PLC
Duration : Period :
Immunocore Holdings plc Technical Analysis Chart | IMCR | US45258D1054 | MarketScreener
Technical analysis trends IMMUNOCORE HOLDINGS PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2 349,99 GBX
Average target price 4 291,74 GBX
Spread / Average Target 82,6%
EPS Revisions
Managers and Directors
Bahija Jallal Chief Executive Officer & Director
Brian R. DiDonato Chief Financial Officer & Head-Strategy
John Irving Bell Chairman
David Berman Head-Research & Development
Travis Coy Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOCORE HOLDINGS PLC-14.87%1 337
MODERNA, INC.-43.98%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-26.74%39 122
SEAGEN INC.-5.21%26 976
ICON PUBLIC LIMITED COMPANY-32.47%17 002